Trial Profile
A Phase II Study of Pazopanib in Combination With Capecitabine and Oxaliplatin (CAPEOX) in Patients With Advanced Gastric Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Mar 2017
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Oxaliplatin (Primary) ; Pazopanib (Primary)
- Indications Gastric cancer
- Focus Therapeutic Use
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 02 Jun 2015 Status changed from recruiting to completed, as reported at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 13 Jun 2013 Planned end date changed from 1 May 2012 to 1 Jun 2015 as reported by ClinicalTrials.gov.